Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition comprising ginsenosides Rh3, PPD and Rh2

A technology of ginsenosides and compositions, which is applied in the field of rare ginsenosides Rh3/PPD/Rh2 compositions, and can solve problems such as anti-tumor effects that have not been reported yet

Active Publication Date: 2020-07-31
SHAANXI GIANT BIOTECHNOLOGY CO LTD
View PDF8 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, no one has reported the antitumor effect of rare ginsenoside compositions with fewer sugar groups and less polarity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition comprising ginsenosides Rh3, PPD and Rh2
  • Pharmaceutical composition comprising ginsenosides Rh3, PPD and Rh2
  • Pharmaceutical composition comprising ginsenosides Rh3, PPD and Rh2

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0079] Example 1 Ginsenoside Rh3, ginsenoside PPD, ginsenoside Rh2, and ginsenoside Rh3 / PPD / Rh2 compositions, Rh3 / PPD compositions, PPD / Rh2 compositions, and Rh3 / Rh2 compositions have effects on gastric cancer cells, liver cancer cells, Inhibition of pancreatic cancer cells

[0080] The aqueous solutions of Rh3, PPD and Rh2 with a concentration of 150ug / mL were prepared respectively. According to the weight ratio of ginsenoside Rh3:PPD:Rh2 respectively 1:1:1, 1:1:2, 1:2:1, 1:0.5:0.5, 1:3:3 to prepare the total concentration of 150ug / mL containing Rh3 , PPD, the aqueous solution of Rh2, it is referred to as composition 1, composition 2, composition 3, composition 4, composition 5; Press ginsenoside Rh3:PPD, PPD:Rh2, Rh3:Rh2 weight ratio is 1 respectively :1:, 1:2, 1:2 to prepare the aqueous solution containing Rh3, PPD with a total concentration of 150ug / mL; PPD:Rh2, Rh3:Rh2, which are referred to as composition 6, composition 7, and composition 8; Ginsenoside Rh3:PPD, PPD:Rh...

Embodiment 2

[0097] Example 2 Effects of Ginsenoside Rh3, Ginsenoside PPD, Ginsenoside Rh2, and Ginsenoside Rh3 / PPD / Rh2 Composition 2, Composition 6, Composition 7, and Composition 8 on Inducing Gastric Cancer Cell Apoptosis

[0098] Taking gastric cancer cells as an example, the cells were inoculated in a sterile 6-well plate, and after 24 hours of culture, 150ug / mL ginsenoside Rh3; 150ug / mL ginsenoside PPD; 150ug / mL ginsenoside Rh2 and 150ug / mL Ginsenoside composition, ginsenoside composition is ginsenoside composition 2, composition 6, composition 7, composition 8 in embodiment 1. An equal volume of 1640 culture solution was added to the control group, and 5 replicate wells were set for each concentration. After culturing for 24 hours, add ice-cold PBS to wash 2-3 times, add 1×Binding Buffer buffer, pipette evenly, then drop an appropriate amount of AV / PI mixed dye solution, incubate for 15 minutes in the dark, and use flow cytometry to detect cell apoptosis Death.

[0099] figure 1 ...

Embodiment 3

[0104] Example 3 Effects of ginsenoside Rh3, ginsenoside PPD, ginsenoside Rh2, and ginsenoside Rh3 / PPD / Rh2 compositions 2, 6, 7, and 8 on the cycle distribution of gastric cancer cells

[0105] Taking gastric cancer cells as an example, the cells in the logarithmic growth phase were divided into 1×10 5 Inoculate each well in a 6-well plate, add ginsenoside Rh3, ginsenoside PPD, ginsenoside Rh2, and composition 2, composition 6, composition 7, and composition 8 at a final concentration of 150 μg / mL, and add and add drugs to the control group Set an equal volume of RPMI-1640 culture solution, and set 5 duplicate wells for each concentration. After continuing to act for 48 hours, the cells were digested and centrifuged, the supernatant was removed, washed 2-3 times by adding 4°C pre-cooled PBS, then added 4°C pre-cooled 75% ethanol, and fixed overnight at 4°C. The next day, discard the supernatant by centrifugation, then add 4°C pre-cooled PBS to wash 2-3 times, add an appropria...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a pharmaceutical composition comprising ginsenosides Rh3, PPD, and Rh2. The pharmaceutical composition is a rare ginsenoside pharmaceutical composition with an anti-tumor effect. The rare pharmaceutical composition comprises treatment effective amounts of ginsenoside Rh3, ginsenoside PPD and ginsenoside Rh2 as effective components, and comprises a pharmaceutically acceptable carrier, wherein and the weight ratio of the ginsenoside Rh3 to the ginsenoside PPD to the ginsenoside Rh2 in the rare ginsenoside pharmaceutical composition is 1:(1-2):(1-2). Experimental results show that the inhibition rate of the pharmaceutical composition on tumor cells is obviously increased compared with the inhibition rate of a single ginsenoside group, the combined index (CI) values are all greater than 0.8, and combined use of the three ginsenosides have a strong synergistic effect.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to a rare ginsenoside Rh3 / PPD / Rh2 composition with antitumor activity. Background technique [0002] Tumor is one of the malignant diseases with the highest fatality rate in the world, which seriously endangers human life and health. The incidence of cancer in my country exceeds 3 million people every year, and the incidence of lung cancer, breast cancer, and gastric cancer is increasing year by year. In the past 30 years, the mortality rate of breast cancer has increased by 96%, and the mortality rate of lung cancer has increased by 465%. Therefore, the prevention and control of cancer in our country is urgent and the situation is grim. [0003] At present, the most common methods for treating cancer include surgery, radiotherapy, chemotherapy, and biological therapy. These methods have obvious limitations and have certain side effects on the patient's body. Surgical therapy should tak...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/704A61K31/575A61P35/00
CPCA61K31/704A61K31/575A61P35/00A61K2300/00
Inventor 范代娣范翠英段志广马晓轩
Owner SHAANXI GIANT BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com